New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology

Michael E Franks; Gordon R Macpherson; Erin R Lepper; William D Figg; Alex Sparreboom

doi:10.1016/j.drup.2003.09.002

New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology

Drug Resist Updat. 2003 Dec;6(6):301-12. doi: 10.1016/j.drup.2003.09.002.

Authors

Michael E Franks¹, Gordon R Macpherson, Erin R Lepper, William D Figg, Alex Sparreboom

Affiliation

¹ Clinical Pharmacology Research Core, Center for Cancer Research, National Cancer Institute, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA.

PMID: 14744494
DOI: 10.1016/j.drup.2003.09.002

Abstract

The 94th Annual Meeting of the American Association for Cancer Research (AACR) was held from July 11 to 14, 2003 in Washington, DC, and provided an overview of the latest developments in the field of cancer. This report provides highlights of presentations on array-based and RNA-interference technologies to study cancer biology and molecular pharmacology of anticancer drugs, mechanisms and modulation of drug resistance patterns, recent developments in the treatment of prostate cancer, and the medicinal chemistry of established and novel anticancer drugs.

Publication types

Congress

MeSH terms

American Cancer Society
Antineoplastic Agents / pharmacology*
Biomedical Research / trends*
Drug Design*
Drug Resistance, Neoplasm*
Neoplasms / drug therapy*

Substances

Antineoplastic Agents